<DOC>
	<DOCNO>NCT01512472</DOCNO>
	<brief_summary>Men localize prostate cancer require intermittent androgen deprivation therapy biochemical recurrence follow radical therapy ask participate phase 4 safety efficacy clinical trial compare 10 month versus 4 month degarelix ( Firmagon® ) therapy endpoint prolong treatment interval .</brief_summary>
	<brief_title>Firmagon ( Degarelix ) Intermittent Therapy</brief_title>
	<detailed_description>This open-label , multi-centre , randomised trial subject receive subcutaneous ( s.c. ) monthly injection degarelix depot . All patient treat one-month start dose 240mg Day 0 . Subjects randomize receive either nine three maintenance dose one month duration . The primary objective determine effect degarelix therapy length treatment interval ( defined serum Prostate-specific antigen ( PSA ) increase 5 ng/ml ) follow completion androgen deprivation therapy . The trial also assess effect degarelix therapy PSA kinetics ( specifically PSA double time ) , PSA nadir , effect quality life well measure . The efficacy safety two treatment also report .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>histologically confirm adenocarcinoma prostate intermittent endocrine treatment therapy indicate PSA level meeting criterion : PSA level ≥ 5 ng/mL . For patient recurrence radiotherapy cryotherapy : Patients serum PSA ( two measurement ) &gt; 2 ng/mL high previously confirm PSA nadir . screen serum testosterone level lower limit normal range define &gt; 2.2 ng/mL . Has previous currently hormonal management prostate cancer ( surgical castration hormonal manipulation ) Has receive therapy 5alpha reductase inhibitor finasteride dutasteride within 12 week 25 week , respectively , prior screen</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>localized prostate cancer</keyword>
	<keyword>degarelix</keyword>
	<keyword>intermittent androgen deprivation therapy</keyword>
</DOC>